Drug Profile
Autologous stem cell therapy - Acer Therapeutics
Alternative Names: MDIs - AcerLatest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Opexa Therapeutics
- Developer Acer Therapeutics; Opexa Therapeutics
- Class Cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements; Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
- Discontinued Heart failure
Most Recent Events
- 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Implant)
- 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics